SIMBRINZA® (BRINZOLAMIDE/BRIMONIDINE TARTRATE OPHTHALMIC SUSPENSION)

Simbrinza® is a combination ophthalmic medication used for the treatment of glaucoma or ocular hypertension. It was recently approved on provincial formularies. Simbrinza® contains two medications that reduce intraocular pressure: brinzolamide, a carbonic anhydrase inhibitor, and brimonidine tartrate, an alpha-adrenergic agonist.

- **Dosage:** One drop in the affected eye(s) two times daily.
- **Uses:** To reduce intraocular pressure in:
  - Residents with open-angle glaucoma
  - Residents who have ocular hypertension and have not responded to treatment with a single medication product
- **Avoid** in residents who:
  - Have severe kidney impairment
  - Are on certain antidepressants (e.g., MAO Inhibitors, tricyclic antidepressants [TCAs])
  - Have allergies to sulfonamides
- Single medication products that contain these ingredients include Azopt® (brinzolamide) and Alphagan® (brimonidine)

**Eye changes**
- Blurriness, redness, allergies

**Decreased mental alertness**

**Low blood pressure**

**Signs of metabolic acidosis**
- (e.g., rapid breathing)

Please refer to the Simbrinza® product monograph for more comprehensive information regarding this medication.

References: